Interim evaluation of our experience with infliximab treatment in IBD

Introduction: Infliximab (IFX) became an accepted treatment modality in active luminal disease and for enterocutaneous fistulae in patients suffering from Crohn's disease (CD). Aims: Retrospective evaluation of our experience with IFX treatment from three different standpoints: (1) routine (standard and maintenance) IFX treatment in CD. (2) effects of initial (step-down) IFX therapy in CD, (3) possibilities of IFX treatment in ulcerative colitis (UC). Material and methods: (1) Standard and maintenance IFX treatment was introduced in 49 CD patients with fistulae or steroid-resistent cases. Indicators were: proven…